Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | CYP24A1 | Q07973 | 3/20 | 0.41 |
| ▸ | GCGR | P47871 | 2/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | GIPR | P48546 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647552 | 1.00 | EPHX2 (0.48) | EPHX2NR1H4ALDH1A1NPC1RAB9A | |
| SCHEMBL2647793 | 0.83 | ALDH1A1 (0.54) | EPHX2NR1H4ALDH1A1NPC1RAB9A | |
| SCHEMBL2647795 | 0.83 | ALDH1A1 (0.54) | EPHX2NR1H4ALDH1A1NPC1RAB9A | |
| SCHEMBL13760116 | 0.83 | NPC1 (0.42) | ALDH1A1NPC1RAB9ASMN1; SMN2CYP24A1 | |
| SCHEMBL7096522 | 0.81 | NPC1 (0.66) | EPHX2NPC1RAB9ASMN1; SMN2GAA | |
| Benzene SCHEMBL8722272 | 0.81 | NPC1 (0.66) | EPHX2NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1663138 | 0.81 | ALDH1A1 (0.49) | EPHX2NR1H4ALDH1A1NPC1RAB9A | |
| SCHEMBL14596376 | 0.77 | EPHX2 (0.51) | EPHX2NR1H4ALDH1A1ADRB2ADRB1 | |
| SCHEMBL12326089 | 0.77 | PLK1 (0.54) | EPHX2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12641858 | 0.77 | GAA (0.57) | EPHX2NR1H4ALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | disclosed |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2004-02-05 | — | — | US | disclosed |
| US-6562807-B2 | For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity | NOVO NORDISK A/S (DK) | 2003-05-13 | — | — | US | disclosed |
| EP-1296942-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | Novo Nordisk A/S (DK) | 2003-04-02 | — | — | EP | disclosed |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2002-10-03 | — | — | US | disclosed |
| WO-2002000612-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | EPHX2 3116/4885NR1H4 98/4885ALDH1A1 4046/4885 |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | EPHX2 3116/4885NR1H4 98/4885ALDH1A1 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.